Breast Surgery Practice Questions

Q: Which of the following statements is true with respect to discharge of blood from the nipple, EXCEPT?

It is occasionally normal. ### Explanation **Core Concept:** Nipple discharge is a common clinical presentation in breast surgery. The key to answering this question lies in distinguishing between **pathological** and **physiological** discharge. **Bloody (sanguineous) nipple discharge is never considered normal.** It is always a pathological sign that mandates a thorough investigation to rule out malignancy. **Why Option A is the Correct Answer (The "Except" Statement):** Bloody discharge is **never "occasionally normal."** While milky discharge (galactorrhea) or greenish/brownish discharge (duct ectasia) can sometimes be physiological or related to benign hormonal changes, the presence of blood indicates an underlying lesion (either benign or malignant) that has eroded the ductal lining. **Analysis of Incorrect Options:** * **B. Suggests duct papilloma:** This is the **most common cause** of spontaneous, single-duct bloody nipple discharge. It is a benign epithelial growth within the duct. * **C. Suggests carcinoma breast:** In approximately 5–15% of cases, bloody nipple discharge is the presenting symptom of malignancy, most commonly **Ductal Carcinoma In Situ (DCIS)** or invasive papillary carcinoma. * **D. Always needs further evaluation:** Because of the risk of malignancy, any patient presenting with bloody discharge must undergo the "Triple Assessment" (Clinical examination, Imaging like Mammography/Ultrasound, and Cytology/Biopsy). **NEET-PG High-Yield Pearls:** * **Most common cause of bloody nipple discharge:** Intraductal Papilloma. * **Most common cause of nipple discharge overall:** Duct Ectasia (usually multicolored/sticky). * **Investigation of Choice:** For a specific leaking duct, **Microdochectomy** (excision of the single involved duct) is both diagnostic and therapeutic. * **Risk Factor:** Bloody discharge in a post-menopausal woman or associated with a palpable mass significantly increases the suspicion of breast cancer.

Q: Inflammatory carcinoma is classified under which TNM staging category?

T4d. ### Explanation **Correct Answer: D. T4d** **Medical Concept:** Inflammatory Breast Cancer (IBC) is a distinct, highly aggressive clinical entity characterized by rapid onset of erythema, edema (peau d'orange), and warmth involving at least one-third of the breast. In the TNM staging system (AJCC 8th Edition), IBC is specifically categorized as **T4d**. This classification is based on **clinical findings** rather than purely pathological ones, as the hallmark "dermal lymphatic invasion" by tumor emboli is not required for the diagnosis if the clinical criteria are met. **Analysis of Incorrect Options:** * **T4a:** Refers to tumor extension to the **chest wall** (involvement of ribs, intercostal muscles, or serratus anterior; pectoralis muscle involvement alone does not qualify). * **T4b:** Refers to **skin changes** such as edema (including peau d'orange), ulceration, or satellite skin nodules, but these do *not* meet the criteria for inflammatory carcinoma (i.e., they involve less than one-third of the breast). * **T4c:** Represents a combination of both **T4a and T4b** (extension to chest wall plus skin ulceration/edema). **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Diagnosis:** IBC is primarily a clinical diagnosis. The classic **"Peau d'orange"** appearance is due to the obstruction of dermal lymphatics by tumor emboli. * **Staging:** All T4d tumors are automatically classified as at least **Stage IIIB**, regardless of nodal status (if N0). * **Management:** The standard of care is **Multimodality Therapy**: Neoadjuvant Chemotherapy (NACT) followed by Modified Radical Mastectomy (MRM) and Radiotherapy. *Never* start with primary surgery. * **Differential Diagnosis:** Must be differentiated from acute mastitis; if a suspected "breast infection" does not respond to antibiotics within 1–2 weeks, a biopsy is mandatory to rule out IBC.

Q: What is the general trend of the incidence of breast cancer with increasing age?

Increases with increasing age. **Explanation:** **1. Why Option A is Correct:** The single most significant risk factor for breast cancer is **increasing age**. The incidence follows a linear progression: it is rare before age 25, increases rapidly after age 30, and continues to rise throughout a woman’s lifetime, peaking in the 6th and 7th decades. This is primarily due to the cumulative exposure of breast tissue to endogenous hormones (estrogen/progesterone) and the time-dependent accumulation of genetic mutations in mammary epithelial cells. **2. Why Other Options are Incorrect:** * **Option B:** The incidence has **not declined**; rather, it has increased since the 1940s due to better screening (mammography), changes in reproductive patterns (later first pregnancy, nulliparity), and increased life expectancy. * **Option C:** While obesity (especially post-menopausal) is a known risk factor due to peripheral conversion of androstenedione to estrone in adipose tissue, a **direct causal link** between specific dietary fat intake and breast cancer remains controversial and is not the "general trend" of incidence. * **Option D:** There is no established scientific evidence linking coffee intake to an increased risk of breast cancer. In fact, some studies suggest caffeine may have a protective effect or no effect at all. **Clinical Pearls for NEET-PG:** * **Most common site:** Upper Outer Quadrant (45-50%). * **Protective factors:** Early pregnancy (<20 years), breastfeeding, and late menarche. * **Gail Model:** The most commonly used tool to estimate the individualized risk of developing breast cancer. * **High-Yield Fact:** In India, breast cancer has overtaken cervical cancer to become the most common cancer among women in urban populations, with a trend toward affecting a younger age group compared to Western countries.

Q: Adjuvant therapy after mastectomy is needed in all of the following situations except:

Low risk, no node. **Explanation:** The decision to initiate adjuvant therapy (chemotherapy, hormonal therapy, or radiotherapy) after a mastectomy is based on the risk of systemic recurrence and the biological profile of the tumor. **Why "Low risk, no node" is the correct answer:** Adjuvant therapy is generally withheld in patients with **low-risk, node-negative (N0)** disease. This typically includes patients with small tumors (usually <0.5 cm or T1a), favorable histological subtypes (e.g., tubular or mucinous carcinoma), and strongly hormone-receptor-positive status with a low proliferative index (Ki-67). In these cases, the risk of recurrence is so low that the potential toxicities of chemotherapy outweigh the marginal clinical benefit. **Analysis of Incorrect Options:** * **High risk, node positive:** Presence of even a single positive lymph node (N1 or higher) significantly increases the risk of systemic spread, making adjuvant systemic therapy (usually chemotherapy) mandatory. * **ER/PR negative:** Tumors that lack hormone receptors do not respond to endocrine therapy (like Tamoxifen). Because these "Triple Negative" or "Basal-like" cancers are more aggressive, adjuvant chemotherapy is indicated even for relatively small tumors. * **Her-2-neu positive:** Overexpression of the HER2 protein signifies an aggressive phenotype. These patients require adjuvant chemotherapy combined with targeted therapy (e.g., Trastuzumab) to improve survival outcomes. **Clinical Pearls for NEET-PG:** * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for axillary staging in clinically N0 patients to determine the need for adjuvant therapy. * **Oncotype DX:** A genomic assay used specifically in ER+, HER2-, node-negative patients to decide if chemotherapy can be safely omitted. * **Radiotherapy after Mastectomy (PMRT):** Indicated if the tumor is >5 cm (T3), involves the chest wall/skin (T4), or if there are ≥4 positive nodes.

Q: Which of the following is considered a bad prognostic sign for carcinoma of the breast?

HER2 receptor. In breast carcinoma, prognosis is determined by clinical, pathological, and molecular markers. The status of hormone receptors (ER, PR) and growth factor receptors (HER2/neu) is critical for predicting both the aggressiveness of the tumor and the response to therapy. **Why HER2 receptor is the correct answer:** The **HER2/neu (Human Epidermal Growth Factor Receptor 2)** is a proto-oncogene. Its overexpression (found in 15-20% of breast cancers) leads to increased cell proliferation and survival. Clinically, HER2-positive status is associated with a **more aggressive tumor phenotype**, higher grade, increased risk of recurrence, and overall poorer prognosis compared to hormone receptor-positive tumors. While targeted therapies like Trastuzumab have improved outcomes, it remains a marker of high biological aggression. **Why the other options are incorrect:** * **Estrogen Receptor (ER) and Progesterone Receptor (PR):** These are **good prognostic markers**. Their presence indicates that the tumor is well-differentiated and "hormone-dependent." Patients with ER/PR-positive tumors generally have a slower disease progression and a favorable response to endocrine therapies (e.g., Tamoxifen or Aromatase Inhibitors). **High-Yield Clinical Pearls for NEET-PG:** * **Triple Negative Breast Cancer (TNBC):** Lacks ER, PR, and HER2. It has the worst prognosis among all molecular subtypes. * **Luminal A:** (ER/PR+, HER2-) has the best prognosis. * **Nottingham Prognostic Index (NPI):** Uses tumor size, lymph node status, and histological grade to predict survival. * **Most important prognostic factor:** Axillary lymph node status (number of nodes involved). * **Most important predictive factor:** Receptor status (determines response to specific drugs).

Q: Which of the following is not a risk factor for breast carcinoma?

Early menopause. **Explanation:** The risk of breast carcinoma is primarily linked to the **cumulative lifetime exposure of breast tissue to estrogen**. Estrogen promotes the proliferation of mammary epithelial cells, increasing the likelihood of DNA mutations. **Why Early Menopause is the Correct Answer:** Early menopause (cessation of menstruation before age 45) is actually a **protective factor**, not a risk factor. It shortens the duration of the "estrogen window," thereby reducing the total lifetime exposure to ovarian hormones. Conversely, **late menopause** (after age 55) is a well-known risk factor. **Analysis of Incorrect Options:** * **Saturated Fatty Acids:** High dietary intake of saturated fats and obesity (especially post-menopausal) are linked to increased risk. In obese women, peripheral conversion of androstenedione to estrone in adipose tissue increases circulating estrogen levels. * **Nulliparous Women:** Women who have never carried a pregnancy to term have higher risk because they do not experience the hormonal "break" provided by pregnancy and lactation. Early first pregnancy (before age 20) is protective. * **Estrogen Unopposed by Progesterone:** Prolonged exposure to estrogen without the balancing effect of progesterone (e.g., Hormone Replacement Therapy or early menarche) stimulates ductal hyperplasia, increasing malignancy risk. **High-Yield Clinical Pearls for NEET-PG:** * **The "Estrogen Window" Concept:** Risk increases with early menarche ( 55 years). * **BRCA Mutations:** BRCA1 (Chromosome 17) and BRCA2 (Chromosome 13) are the most significant genetic risk factors. * **Breastfeeding:** For every 12 months of breastfeeding, the relative risk of breast cancer decreases by approximately 4.3%. * **Atypical Hyperplasia:** Finding atypical ductal or lobular hyperplasia on biopsy increases risk by 4–5 times.

Question 1

In a patient with carcinoma breast stage T4b, as per TNM classification, what defines this stage?

Accepted Answer

Nipple retraction

Answer

Skin ulcer over the swelling

Answer

Dermal edema

Answer

Satellite nodules

Question 2

In a post-mastectomy patient, the suction drain is accidentally removed on the 2nd post-operative day, and the patient presents with oozing and swelling in the chest. What is the next best step in management?

Accepted Answer

Aspiration under aseptic conditions and apply pressure dressing

Answer

Open incision and pack with saline gauze

Answer

Reinsert the drain

Answer

Wait and watch

Question 3

Which of the following statements is true with respect to discharge of blood from the nipple, EXCEPT?

Accepted Answer

It is occasionally normal

Answer

Suggests duct papilloma

Answer

Suggests carcinoma breast

Answer

Always needs further evaluation

Question 4

Inflammatory carcinoma is classified under which TNM staging category?

Accepted Answer

T4d

Answer

T4a

Answer

T4b

Answer

T4c

Question 5

What is the general trend of the incidence of breast cancer with increasing age?

Accepted Answer

Increases with increasing age

Answer

Has declined significantly since the 1940s

Answer

Is directly related to dietary fat intake

Answer

Is directly related to coffee intake

Question 6

A 35-year-old female patient presents with a hard nodule approximately 1 cm in diameter, located slightly above and lateral to her right areola. A dye is injected into the tissue around the tumor, and lymphatic vessels draining the area are exposed by incision. These vessels, which uptake the visible dye, are traced to surgically expose the lymph nodes receiving lymph from the tumor. Which of the following lymph nodes will most likely first receive lymph drainage from this tumor?

Accepted Answer

Anterior axillary (pectoral) nodes

Answer

Rotter interpectoral nodes

Answer

Parasternal nodes along the internal thoracic artery and vein

Answer

Central axillary nodes

Question 7

Adjuvant therapy after mastectomy is needed in all of the following situations except:

Accepted Answer

Low risk, no node

Answer

High risk, node positive

Answer

Estrogen receptor/Progesterone receptor negative

Answer

Her-2-neu positive

Question 8

A 30-year-old female underwent lumpectomy for a 1.2x1 cm breast lesion with positive axillary nodes. She received adjuvant radiotherapy, tamoxifen, and chemotherapy. What is the recommended line of management for her follow-up?

Accepted Answer

Examination once every 3 months for one year, followed by yearly mammograms

Answer

Yearly bone scans

Answer

Liver function tests every 6 months

Answer

Follow-up by tumor markers every 6 months

Question 9

Which of the following is considered a bad prognostic sign for carcinoma of the breast?

Accepted Answer

HER2 receptor

Answer

Progesterone receptor

Answer

Estrogen receptor

Answer

None of the above

Question 10

Which of the following is not a risk factor for breast carcinoma?

Accepted Answer

Early menopause

Answer

Saturated fatty acids

Answer

Nulliparous women

Answer

Estrogen unopposed by progesterone

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?